Current Potential Therapeutic Approaches against SARS-CoV-2: A Review

被引:6
|
作者
Yadav, Dharmendra Kumar [1 ,2 ]
Singh, Desh Deepak [3 ]
Han, Ihn [4 ]
Kumar, Yogesh [5 ]
Choi, Eun-Ha [4 ]
机构
[1] Gachon Univ, Coll Pharm, Gachon Inst Pharmaceut Sci, Hambakmoeiro 191, Incheon 21924, South Korea
[2] Gachon Univ, Coll Pharm, Dept Pharm, Hambakmoeiro 191, Incheon 21924, South Korea
[3] Amity Univ Rajasthan, Amity Inst Biotechnol, Jaipur 303002, Rajasthan, India
[4] Kwangwoon Univ, Dept Elect & Biol Phys, Appl Plasma Med Ctr, Plasma Biosci Res Ctr, Seoul 01897, South Korea
[5] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Martinistr 52 Gebaude N27, D-20246 Hamburg, Germany
基金
新加坡国家研究基金会;
关键词
SARS-CoV-2; combination therapy; virus-based therapy; host-based therapy; SARS-CoV-2 cell entry inhibitors; MECHANISMS; TMPRSS2;
D O I
10.3390/biomedicines9111620
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection and replication have been proposed. These medicines include inhibitors of serine protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2). The S protein of SARS-CoV-2 binds to the receptor in host cells. ACE2 inhibitors block TMPRSS2 and S protein priming, thus preventing SARS-CoV-2 entry to host cells. Moreover, antiviral medicines (including the nucleotide analogue remdesivir, the HIV protease inhibitors lopinavir and ritonavir, and wide-spectrum antiviral antibiotics arbidol and favipiravir) have been shown to reduce the dissemination of SARS-CoV-2 as well as morbidity and mortality associated with COVID-19.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Nanoparticle approaches against SARS-CoV-2 infection
    Duan, Yaou
    Wang, Shuyan
    Zhang, Qiangzhe
    Gao, Weiwei
    Zhang, Liangfang
    CURRENT OPINION IN SOLID STATE & MATERIALS SCIENCE, 2021, 25 (06):
  • [22] CURRENT CORONAVIRUS (SARS-COV-2) EPIDEMIOLOGICAL, DIAGNOSTIC AND THERAPEUTIC APPROACHES: AN UPDATED REVIEW UNTIL JUNE 2020
    Nabil, Ahmed
    Uto, Koichiro
    Elshemy, Mohamed M.
    Soliman, Reham
    Hassan, Ayman A.
    Ebara, Mitsuhiro
    Shiha, Gamal
    EXCLI JOURNAL, 2020, 19 : 992 - 1016
  • [23] Disinfectants against SARS-CoV-2: A Review
    Xiao, Shuqi
    Yuan, Zhiming
    Huang, Yi
    VIRUSES-BASEL, 2022, 14 (08):
  • [24] Engineered Therapeutic Antibody Against SARS-CoV-2
    Monrat Chulanetra
    Current Clinical Microbiology Reports, 2023, 10 : 222 - 235
  • [25] Engineered Therapeutic Antibody Against SARS-CoV-2
    Chulanetra, Monrat
    CURRENT CLINICAL MICROBIOLOGY REPORTS, 2023, 10 (04) : 222 - 235
  • [26] Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches
    Sodagar, Aisha
    Javed, Rasab
    Tahir, Hira
    Abd Razak, Saiful Izwan
    Shakir, Muhammad
    Naeem, Muhammad
    Yusof, Abdul Halim Abdul
    Sagadevan, Suresh
    Hazafa, Abu
    Uddin, Jalal
    Khan, Ajmal
    Al-Harrasi, Ahmed
    BIOMOLECULES, 2022, 12 (07)
  • [27] Potential Therapeutic Target and Vaccines for SARS-CoV-2
    Hussain, Mohamed A.
    Hassan, Mohamed M.
    Bashir, Bashir Abdrhman
    Gamar, Tarig A.
    Gasmalbari, Elmuaiz
    Mohamed, Ahmed Osman
    Osman, Wadah
    Sherif, Asmaa E.
    Elgaml, Abdelaziz
    Alhaddad, Aisha A.
    Ghazawi, Kholoud F.
    Miski, Samar F.
    Ainousah, Bayan E.
    Andijani, Yusra Saleh
    Ibrahim, Sabrin R. M.
    Mohamed, Gamal A.
    Ashour, Ahmed
    PATHOGENS, 2023, 12 (07):
  • [28] Current state of vaccination against SARS-CoV-2
    Iking-Konert, Christof
    Specker, Christof
    Krueger, Klaus
    Schulze-Koops, Hendrik
    Aries, Peer
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2021, 80 (02): : 158 - 164
  • [29] Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms
    Majnooni, Mohammad Bagher
    Fakhri, Sajad
    Bahrami, Gholamreza
    Naseri, Maryam
    Farzaei, Mohammad Hosein
    Echeverria, Javier
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [30] Computational Study of the Therapeutic Potential of Novel Heterocyclic Derivatives against SARS-CoV-2
    Babalola, Benjamin Ayodipupo
    Adetobi, Tosin Emmanuel
    Akinsuyi, Oluwamayowa Samuel
    Adebisi, Otunba Ahmed
    Folajimi, Elizabeth Oreoluwa
    COVID, 2021, 1 (04): : 757 - 774